Cargando…
A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer
Colorectal cancer is a common and often deadly cancer. Circulating tumor cells (CTCs) have been implicated as a potentially valuable prognosis factor. The detection of circulating tumor microemboli (CTM) and of simple blood component parameters that reflect inflammatory status, such as the platelet-...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649529/ https://www.ncbi.nlm.nih.gov/pubmed/33157516 http://dx.doi.org/10.1016/j.tranon.2020.100932 |
_version_ | 1783607348709818368 |
---|---|
author | Abdallah, Emne Ali Souza e Silva, Virgílio Braun, Alexcia Camila Gasparini, Vanessa Alves Kupper, Bruna Elisa Catin Tariki, Milena Shizue Tarazona, José Gabriel Rodriguez Takahashi, Renata Mayumi Aguiar Júnior, Samuel Chinen, Ludmilla Thomé Domingos |
author_facet | Abdallah, Emne Ali Souza e Silva, Virgílio Braun, Alexcia Camila Gasparini, Vanessa Alves Kupper, Bruna Elisa Catin Tariki, Milena Shizue Tarazona, José Gabriel Rodriguez Takahashi, Renata Mayumi Aguiar Júnior, Samuel Chinen, Ludmilla Thomé Domingos |
author_sort | Abdallah, Emne Ali |
collection | PubMed |
description | Colorectal cancer is a common and often deadly cancer. Circulating tumor cells (CTCs) have been implicated as a potentially valuable prognosis factor. The detection of circulating tumor microemboli (CTM) and of simple blood component parameters that reflect inflammatory status, such as the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR), may provide information about tumor progression. The aim of this study was to explore the importance of CTCs, CTM, PLR, and NLR prospectively in non-metastatic colon cancer progression. CTCs were enriched using ISET(Ⓡ) (Isolation by SizE of Tumor cells) and identified by immunocytochemical exclusion of leukocytes. We evaluated CTCs and blood cell parameters in a cohort of 69 stage I–III colon cancer patients (52.2% men; median age, 61 years; age range, 19–87 years) at a baseline timepoint prior to resection surgery. The median of CTC levels at baseline was 20 cells/8 mL (0–94) and higher levels were associated with CTM presence (p = 0.02). CTM were found in 18 (26.1%) patients. Of 18 stage I patients, 33.3% had CTM and of 51 stages II or III patients, 13.7% had CTM (p = 0.08). Patients with a high PLR (>124) were mostly (75.6%) diagnosed with high-risk stages II/III cancer (stages I/low-risk II, 24.4%; p = 0.014). All 8 patients that had disease recurrence during follow-up had a high PLR (p = 0.02 vs. low PLR). NLR was not significantly associated with disease stage or recurrence. The present results indicate that CTCs and PLR analyses may be clinically useful for colon cancer management and risk stratification. |
format | Online Article Text |
id | pubmed-7649529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-76495292020-11-17 A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer Abdallah, Emne Ali Souza e Silva, Virgílio Braun, Alexcia Camila Gasparini, Vanessa Alves Kupper, Bruna Elisa Catin Tariki, Milena Shizue Tarazona, José Gabriel Rodriguez Takahashi, Renata Mayumi Aguiar Júnior, Samuel Chinen, Ludmilla Thomé Domingos Transl Oncol Original article Colorectal cancer is a common and often deadly cancer. Circulating tumor cells (CTCs) have been implicated as a potentially valuable prognosis factor. The detection of circulating tumor microemboli (CTM) and of simple blood component parameters that reflect inflammatory status, such as the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR), may provide information about tumor progression. The aim of this study was to explore the importance of CTCs, CTM, PLR, and NLR prospectively in non-metastatic colon cancer progression. CTCs were enriched using ISET(Ⓡ) (Isolation by SizE of Tumor cells) and identified by immunocytochemical exclusion of leukocytes. We evaluated CTCs and blood cell parameters in a cohort of 69 stage I–III colon cancer patients (52.2% men; median age, 61 years; age range, 19–87 years) at a baseline timepoint prior to resection surgery. The median of CTC levels at baseline was 20 cells/8 mL (0–94) and higher levels were associated with CTM presence (p = 0.02). CTM were found in 18 (26.1%) patients. Of 18 stage I patients, 33.3% had CTM and of 51 stages II or III patients, 13.7% had CTM (p = 0.08). Patients with a high PLR (>124) were mostly (75.6%) diagnosed with high-risk stages II/III cancer (stages I/low-risk II, 24.4%; p = 0.014). All 8 patients that had disease recurrence during follow-up had a high PLR (p = 0.02 vs. low PLR). NLR was not significantly associated with disease stage or recurrence. The present results indicate that CTCs and PLR analyses may be clinically useful for colon cancer management and risk stratification. Neoplasia Press 2020-11-03 /pmc/articles/PMC7649529/ /pubmed/33157516 http://dx.doi.org/10.1016/j.tranon.2020.100932 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Abdallah, Emne Ali Souza e Silva, Virgílio Braun, Alexcia Camila Gasparini, Vanessa Alves Kupper, Bruna Elisa Catin Tariki, Milena Shizue Tarazona, José Gabriel Rodriguez Takahashi, Renata Mayumi Aguiar Júnior, Samuel Chinen, Ludmilla Thomé Domingos A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer |
title | A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer |
title_full | A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer |
title_fullStr | A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer |
title_full_unstemmed | A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer |
title_short | A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer |
title_sort | higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649529/ https://www.ncbi.nlm.nih.gov/pubmed/33157516 http://dx.doi.org/10.1016/j.tranon.2020.100932 |
work_keys_str_mv | AT abdallahemneali ahigherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT souzaesilvavirgilio ahigherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT braunalexciacamila ahigherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT gasparinivanessaalves ahigherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT kupperbrunaelisacatin ahigherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT tarikimilenashizue ahigherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT tarazonajosegabrielrodriguez ahigherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT takahashirenatamayumi ahigherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT aguiarjuniorsamuel ahigherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT chinenludmillathomedomingos ahigherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT abdallahemneali higherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT souzaesilvavirgilio higherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT braunalexciacamila higherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT gasparinivanessaalves higherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT kupperbrunaelisacatin higherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT tarikimilenashizue higherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT tarazonajosegabrielrodriguez higherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT takahashirenatamayumi higherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT aguiarjuniorsamuel higherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer AT chinenludmillathomedomingos higherplatelettolymphocyteratioisprevalentinthepresenceofcirculatingtumormicroemboliandisapotentialprognosticfactorfornonmetastaticcoloncancer |